Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCC-2618 (ripretinib) in advanced malignancies
NCT02571036Phase 1Completed
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Nov 2015
- Primary completion
- Apr 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 1, open-label trial of ripretinib in gastrointestinal stromal tumor (GIST), systemic mastocytosis (SM), malignant glioma and 5 more (12 arms), sponsored by Deciphera Pharmaceuticals. Primary endpoints: Incidence of Adverse Events at 24 months, Maximum Tolerated Dose and Recommended Phase 2 Dose at 18 months and 1 more. Started Nov 2015; status: completed.
02
Drugs
ripretinib
03
Conditions
gastrointestinal stromal tumor (GIST)systemic mastocytosis (SM)malignant gliomamelanomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02571036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02571036.